<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Q2 Earnings on FinanClub</title>
    <link>https://finan.club/tags/q2-earnings/</link>
    <description>Recent content in Q2 Earnings on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Aug 2023 07:37:36 +0000</lastBuildDate><atom:link href="https://finan.club/tags/q2-earnings/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title> BTG</title>
      <link>https://finan.club/us/btg/</link>
      <pubDate>Tue, 08 Aug 2023 07:37:36 +0000</pubDate>
      
      <guid>https://finan.club/us/btg/</guid>
      <description>score:1202
Chances: B2Gold&amp;rsquo;s Q2 2023 earnings call discussed operational and financial results, including total gold production and performance highlights. B2Gold&amp;rsquo;s Q2 2023 revenues increased year-over-year due to higher average realized gold prices and increased gold ounces sold. B2Gold delivered positive earnings and revenue surprises for Q2 2023, indicating a potential positive outlook.</description>
    </item>
    
    <item>
      <title> ARRY</title>
      <link>https://finan.club/us/arry/</link>
      <pubDate>Tue, 08 Aug 2023 07:36:58 +0000</pubDate>
      
      <guid>https://finan.club/us/arry/</guid>
      <description>score:1294
Chances: Array Technologies&amp;rsquo; Q2 results may show increased megawatts shipment and strong margin performance from STI Norland acquisition. Array Technologies has an impressive earnings surprise history and a favorable combination for a likely beat in its next quarterly report. The growth of solar energy and technological advancements create opportunities for solar stocks, including Array Technologies.</description>
    </item>
    
    <item>
      <title> CLF</title>
      <link>https://finan.club/us/clf/</link>
      <pubDate>Tue, 08 Aug 2023 07:13:05 +0000</pubDate>
      
      <guid>https://finan.club/us/clf/</guid>
      <description>score:1179
Chances: Cleveland-Cliffs (NYSE: CLF) reported second-quarter results, showing improved automotive volumes, higher prices, and lower steelmaking unit costs. The company&amp;rsquo;s external sales volumes for steel products increased by around 15.4% year over year in Q2. Cleveland-Cliffs stock price rose by 2.3% over the past week, driven by long-term fundamentals.</description>
    </item>
    
    <item>
      <title> MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 08 Aug 2023 07:02:27 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:1154
Chances: Merck reported stronger-than-expected Q2 earnings and raised its 2023 guidance. Keytruda cancer-drug sales drove better-than-expected Q2 revenue and a raised full-year sales forecast. Merck&amp;rsquo;s top-selling products, Keytruda and HPV vaccine Gardasil, experienced strong demand. Cleveland Clinic has started enrolling subjects in a treatment arm evaluating Anixa&amp;rsquo;s breast cancer vaccine with Keytruda.</description>
    </item>
    
    <item>
      <title> NVST</title>
      <link>https://finan.club/us/nvst/</link>
      <pubDate>Tue, 08 Aug 2023 07:00:38 +0000</pubDate>
      
      <guid>https://finan.club/us/nvst/</guid>
      <description>score:1237
Chances: Envista announces successful pricing of $435 million Convertible Senior Notes offering. Consistent growth in Specialty Products &amp;amp; Technologies and Equipment &amp;amp; Consumables segments drive Q2 revenues. Envista delivers positive Q2 2023 earnings and revenue surprises. Envista Smile Project completes mission trip to the Dominican Republic, providing dental care to underserved patients.</description>
    </item>
    
    <item>
      <title> IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Tue, 08 Aug 2023 06:01:45 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:976
Chances: ImmunoGen, Inc. (IMGN) reports encouraging Q2 earnings with positive adoption of its sole-marketed drug Elahere, showing promising growth potential. The company&amp;rsquo;s strong Q2 financial results included significant positive surprises in both earnings and revenue, indicating a potential upward trend in the stock&amp;rsquo;s performance.</description>
    </item>
    
  </channel>
</rss>
